Indivior Share Discussion Threads

[farmsted] 13/7/2015 12:10

Charts out of date, nice rise in share price today must be some news leaking.

[melody9999] 04/6/2015 22:11

Good performance on a poor day for the markets. Looks ready to break 240 and go on to new highs. Has a great 100 score on Stockopedia. DYOR

[bamboo2] 02/6/2015 17:01

Breakout of pennant confirmed for a target of approx 257



edited
040615 07:42

[bamboo2] 26/5/2015 09:48

taken a few, based on chart potential.

[bamboo2] 25/5/2015 22:30

daily, unconfirmed

[gregmorg] 13/5/2015 16:16

I just couldn't get to the AGM at Grosvenor Square today although, at 4pm, note no AGM statement has been issued. Assume the company had nothing extra of substance to say.

Having said that, look at the announcements! A whole lot of directors have individually bought shares at a price around 229p so their very upbeat view has been backed in the best time honored way of putting their money etc etc. As a shareholder it's very reassuring to see even if I haven't quite got my head around their enthusiasm.

[steeplejack] 05/5/2015 16:23

Thanks for that gregmorg.News on the RBP-7000 explains why this stock has motored away from the issue price so positively and(as far as I'm concerned)rather unexpectedly.Any news to do with a meaningful widening of the company's drug portfolio will be well received.

[gregmorg] 05/5/2015 13:51

Webcast just finished and was positive although not a huge amount of extra info. Co will look to review financial guidance at interim stage and acknowledges this could then be revised upwards. Talking to other parties re adding licensing deals to current portfolio and on time guidelines this could happen at any time. Compared it with a licensing deal that happened last year( detail of which I am unsure). I presumed from this the Co is well down the line in discussions.

Second part of the Phase 3 trials, being the open label aspect, will finish sometime next year, maybe early!, and then the NDA, which to my limited knowledge can take up to another year. Indivior could/may do a deal to farm out the distribution of the Schzio drug given its current limited distribution capabilities. Early days here.

Questions re generic competitor tactics and the company's view of competitive trends with standard replies.

Questions on the syndicated loan/debt just completed as it costs 8% pa and expensive. Given Co good cash flows will look to mitigate cost and aim to reduce debt/maybe refinance as the Company's debt rating improves but as the syndication only just completed it is early days.

Overall a short web meeting but positive as far as I could understand.

[gregmorg] 05/5/2015 12:18

So the 1st Qtr is declared and maybe a tad better than expected with talk of upgrading full year guidance later in the year. That of course would be helpful for the intended dividend--highlighted at launch as 40% of net income for this year.

The pipeline also is making progress and it seems to me that is what everything hangs on. The Phase 3 result moves us on to a near certainty of the NDA and quite a new quite big product for 2017. The webcast at 1 pm will throw more light but so far so good.

[philanderer] 14/4/2015 09:33

Bought a very small holding yesterday.

Luck to everyone.


edit:

1 million shares traded already today !

[qs99] 14/4/2015 08:08

looking very strong IMO

[philanderer] 10/4/2015 23:38

Mail market report:

"...There was also a broker boost for drugs firm Indivior, which was spun off from Reckitt at the end of last year, with Jefferies International upgrading its rating to buy from hold with an increased target price of 225p. Indivior shares gained 10.8p at 211.3p"

Read more:

[gregmorg] 10/4/2015 10:57

Also I am told Jeffries issued a "Buy" on the stock presumably to coincide. Whether a full note or just a recommendation I do not know.

[gregmorg] 10/4/2015 10:20

Interesting morning for the Indivior share price as up over 10p i.e. 211p when I last looked. I think the reason is that the 2014 Annual Report is out today and there are warm words in the Chairman's statement talking about an exciting future etc. Doesn't change the near term revenue decline at all but points to a growth market and more compounds etc but in time.

Suspect this may cause the shorts a little anxiety and may be the cause some of the sudden share price rise.

Good to see we have a future with this share but the diligent, and obviously the management, knew that anyway!

[qs99] 01/4/2015 08:45

IMO there have been some significant IMO director purchases, this cannot all be put down to "supporting" share price. They have do they not lots of drugs in trial, so they are closer to the company than anyone else, so could this just be good confidence in where the company is going? DYOR etc, but strong share price movement also IMO suggests a move through £2 soon IMO...

[neurolodger] 27/3/2015 07:30

CEO is buying are we missing something?

[steeplejack] 19/3/2015 15:14

Pharmas have stormed into favour in the last few months!The likes of Shire now higher than the Abbvie bid price.That said,I suspect there's something specific triggering this sustained upward move.

[gregmorg] 19/3/2015 12:49

No idea and yes an rather irritating move !

I am not so sure your comments re pessimism etc are valid although would be very happy for you to continue to believe and spread that word. Everyone knew it was going to be a difficult trading year and could be 18 months . That was why R and B could not find buyers at a decent price. However if you look more closely and, for instance plough through the webcast you begin to find longer term gems which could be rather exciting in time.

The directors have bought a lot of shares , especially the CEO and the new FD. Of course for the CEO the £750,000 he has invested of taxed income approx is possibly just a punt and to make investors a bit happier re his option package. On the other hand maybe it tells people he is extremely confident.( mind you, that does not tally with downbeat director speak!)

Why do I find the upward move irritating? Time honoured reasons in that I bought a reasonable number and have been waiting to complete my purchases but am not yet in a position to do so. Still I am half to three quarter pleased!

PS. Bear in mind that QE is helping to drive all markets in the search for yield plus the volume of stock coming out from loose R and B holders might be tailing off a bit. Oh, and it would appear that Pharma's have come a bit more into favour over the last few months.

[ganthorpe] 19/3/2015 11:15

Any ideas why the shares are so strong?
Comments here seem pessimistic.
Balance Sheet looks terrible and Director speak not great.
Any whiffs of takeover?
GAN - holds a few

[bench2] 16/2/2015 18:04

Although Reckitt were unable to sell INDV they have raped and pillaged the company prior to the spin off ..In 2013 they took out $806m and 2014 $849m . So INDV forced to raise $750 in new loans , and we are saddled with liabilities of $1222m vs $747 of assets so negative equity of $475m ........ not a great start . I was hoping they would be able to emulate APH on a grander scale and buy in some other mature drugs , but I am not sure they have the fire power . I normally like free spin offs as they often surprise on the upside ........ but there is only one product to support them and , generic competition can be fierce . Good to see director buying , but they could just be whistling dixie . I will watch and wait to see how this develops .

[steeplejack] 16/2/2015 15:48

Variations on a theme perhaps but this is something of a one trick product pony for now.I think it's sound if unexciting value.Final dividend is set for June 2016,a long way off for what I presume to be the larger of the biannual payments.

[gregmorg] 16/2/2015 09:30

The CEO appears not to be alone within the Company in supporting the share price although, of course, they could all be wrong! The overall market seems to think they are. Fortunately for the believing executives, it gives them a good chance at getting some shares at a reasonable price. Cheap or not and right or wrong ,we shall see.

The last Statement was really quite positive given the envisaged down turn in established revenues. The projected Net Income was, however, on the low side of my expectation.

So I was disappointed with the Net given the projected dividend for the first independent year is 40% of that figure. Nevertheless, there appears to be a lot to play for medium term with the executives stating their belief in the best of traditions i.e their cash! Short term I was surprised by the initial strong upward share price move but admit was delighted as well. Still happy to wait and see this one unfold.